MedPath

Repairing Peri-Anal Fistulas with regenerative cell therapeutics (REP-PAF)

Phase 1
Conditions
Crypto-glandular perianal fistula
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Registration Number
CTIS2022-502659-73-01
Lead Sponsor
Odense University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
75
Inclusion Criteria

Adult patients (>= 18years) with complex PAF (high transsphincteric or suprasphincteric), with involvement of more 30% of the anal sphincter referred to the surgical department at Odense University Hospital for treatment, and who are able to communicate with Danish language, and who are able to communicate with Danish language, and who are having address in the region of southern Denmark during the study

Exclusion Criteria

Signs of suppuration/cavitation around the fistula, Allergy against the antibiotics: Penicillin and streptomycin., Coagulopathy, Pregnancy and lactation (positive HCG test), Verified syphilis, HIV, or hepatitis on screening test, Simple or low anal fistula, which can be treated by simple surgical incision, Ano-vaginal and recto-vaginal fistula, The presence of more than one fistula tract, more than two external orifices or more than one internal orifice, Inflammatory Bowel Disease, Immunosuppression (due to clinical condition or medical therapy), Malignancy within 5 years, Previous radiotherapy of the abdomen and pelvis, BMI under 18.5

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath